DE69836209D1 - Vorbeugung und behandlunhg des hepatozellulären krebses - Google Patents

Vorbeugung und behandlunhg des hepatozellulären krebses

Info

Publication number
DE69836209D1
DE69836209D1 DE69836209T DE69836209T DE69836209D1 DE 69836209 D1 DE69836209 D1 DE 69836209D1 DE 69836209 T DE69836209 T DE 69836209T DE 69836209 T DE69836209 T DE 69836209T DE 69836209 D1 DE69836209 D1 DE 69836209D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
hepatocellular cancer
hepatocellular
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836209T
Other languages
German (de)
English (en)
Inventor
S Economou
H Butterfield
Bruguera Antoni Ribas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of DE69836209D1 publication Critical patent/DE69836209D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69836209T 1997-02-13 1998-02-13 Vorbeugung und behandlunhg des hepatozellulären krebses Expired - Lifetime DE69836209D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3837597P 1997-02-13 1997-02-13
PCT/US1998/002753 WO1998035981A1 (en) 1997-02-13 1998-02-13 Prevention and treatment of hepatocellular cancer

Publications (1)

Publication Number Publication Date
DE69836209D1 true DE69836209D1 (de) 2006-11-30

Family

ID=21899585

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836209T Expired - Lifetime DE69836209D1 (de) 1997-02-13 1998-02-13 Vorbeugung und behandlunhg des hepatozellulären krebses

Country Status (8)

Country Link
US (1) US20020031520A1 (enExample)
EP (1) EP0979239B1 (enExample)
JP (3) JP3816959B2 (enExample)
KR (1) KR100460583B1 (enExample)
CN (2) CN1222536C (enExample)
AU (1) AU6435398A (enExample)
DE (1) DE69836209D1 (enExample)
WO (1) WO1998035981A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058922A2 (en) * 2000-02-10 2001-08-16 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
AU2010309438A1 (en) * 2009-10-22 2012-06-07 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof
US10048271B2 (en) 2012-12-11 2018-08-14 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
WO2016161390A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
CN105126074A (zh) * 2015-09-30 2015-12-09 中国药科大学 多肽afp12在制备抗肿瘤药物中的应用
CN105524884A (zh) * 2016-02-29 2016-04-27 时宏珍 Hla-a0201限制性抗afp抗原特异性ctl的制备方法
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof

Also Published As

Publication number Publication date
WO1998035981A1 (en) 1998-08-20
JP2006188528A (ja) 2006-07-20
JP2001515347A (ja) 2001-09-18
CN1259139A (zh) 2000-07-05
EP0979239B1 (en) 2006-10-18
US20020031520A1 (en) 2002-03-14
JP3816959B2 (ja) 2006-08-30
JP2010222379A (ja) 2010-10-07
AU6435398A (en) 1998-09-08
CN1739791A (zh) 2006-03-01
EP0979239A4 (en) 2002-09-18
KR20000071226A (ko) 2000-11-25
CN1222536C (zh) 2005-10-12
EP0979239A1 (en) 2000-02-16
KR100460583B1 (ko) 2004-12-08

Similar Documents

Publication Publication Date Title
ID25504A (id) Pencegahan dan pengobatan penyakit amiloidogenik
NO20014046D0 (no) Gabapentinderivater for forhindring og behandling av visceral smerte
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
GB9903841D0 (en) Diagnosis and treatment of cancer
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
ATE434444T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20005885D0 (no) Kombinasjonsterapi for behandling av refraktær depresjon
AU6435398A (en) Prevention and treatment of hepatocellular cancer
IL141211A0 (en) Prevention and treatment of viral disease
IL138692A0 (en) Treatment and prevention of vascular disease
NO983512D0 (no) Midler for behandling og forhindring av AIDS
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
GB9811598D0 (en) Diagnosis and treatment of cancer
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
GB9911772D0 (en) Diagnosis and treatment of atherosclerosis
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
EP0733365A3 (en) Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer
EP1190089A4 (en) LIG 72A TREATMENT PROCESS AND VARIANTS THEREOF
DE69713442D1 (de) Thioürazil-Derivate und diese enthaltende Metall-Oberflächebehandlungsmittel
GB2343629B (en) Treatment of cellulite
DE69830169D1 (de) Nachweis und behandlung von krebs
FI971625L (fi) Teräksen lämpökäsittely

Legal Events

Date Code Title Description
8332 No legal effect for de